查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1961133

藥物遞送市場－全球產業規模、佔有率、趨勢、機會、預測：依給藥途徑、應用、區域和競爭格局分類，2021-2031年

Pharmaceutical Drug Delivery Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Route of Administration, By Application, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球藥物輸送市場預計將從 2025 年的 21.2 億美元成長到 2031 年的 29.7 億美元，複合年成長率為 5.76%。

該領域的特點是採用專門的系統和製劑，旨在將治療藥物輸送到特定的生理部位，從而確保最大的醫療療效。市場成長的主要驅動力是全球慢性病盛行率的上升以及生物製藥領域的快速發展，後者需要超越傳統口服給藥方式的精準給藥技術。歐洲製藥工業協會聯合會 (EFPIA) 估計，到 2024 年，歐洲以研發為基礎的製藥業的研發投資將達到 550 億歐元，這充分體現了推動這些先進技術發展的雄厚資金實力。

市場概覽
預測期 2027-2031
市場規模：2025年 21.2億美元
市場規模：2031年 29.7億美元
複合年成長率：2026-2031年 5.76%
成長最快的細分市場 局部給藥
最大的市場 北美洲

然而，由於法規結構對新型遞送系統和複合產品有著嚴格的限制，市場面臨許多障礙。例如，基於奈米技術的載體等先進系統的核准流程十分複雜，通常需要大量的臨床檢驗，且耗費巨額研發成本。這些監管要求提高了市場准入門檻，並可能顯著延緩商業化進程，阻礙創新遞送解決方案快速進入全球市場。

市場促進因素

慢性病和非傳染性疾病的日益增多是全球藥物遞送市場的主要驅動力，因此標靶和緩釋機制的引入勢在必行。在腫瘤學領域，抗體藥物複合體（ADC）和奈米顆粒載體的需求不斷成長，以提高治療指數。根據美國癌症協會於2024年1月發布的《2024年癌症事實與數據》，美國新增癌症病例數預計將首次超過200萬，凸顯了精準遞送系統的重要性。這種流行病學變化促使製造商專注於開發能夠確保長期用藥依從性和療效的製劑和裝置。

同時，為支援複雜藥物製劑和生命週期管理（尤其是不斷擴大的生物製藥研發管線）而增加的研發投入，正在推動這一領域的發展。製藥公司正大力投資，透過創新的給藥方式來解決大分子藥物的穩定性和生物利用度難題。根據2024年9月發布的《2024年美國藥品研究與製造商協會年度會員調查》，會員公司在2023年的研發投入達到了創紀錄的1031億美元，這一資金投入正在加速先進技術的商業化進程。此外，美國食品藥物管理局（FDA）在2024年宣布，其藥物評估與研究中心上年度核准了55種新療法，顯示需要特殊給藥方式的產品種類顯著增加。

市場挑戰

圍繞新型藥物遞送系統的嚴格監管環境是限制全球藥物遞送市場成長的主要阻礙因素。監管機構對複雜產品和先進載體實施嚴格的標準，要求製造商進行廣泛而漫長的臨床試驗以證明其安全性和有效性。這種複雜的核准流程顯著延長了研發週期，並延緩了新型藥物遞送系統的商業化。因此，企業面臨長期的不確定性和投資回報延遲，阻礙了高風險創新計劃的開展，並限制了新產品的上市數量。

這些監理障礙直接轉化為沉重的財務負擔，構成高進入門檻，阻礙市場擴張。對全面檢驗數據的需求迫使製造商將大量資源投入研發階段，這往往使小規模企業在財務上舉步維艱。根據美國製藥製造商協會（PhRMA）預測，其成員公司在2024年的研發支出預計將達到創紀錄的1035億美元，反映出應對這一高要求研發路徑所帶來的成本飆升。這種巨大的財務壓力限制了市場參與者快速推出多樣化解決方案的能力，最終減緩了整個產業的整體發展進程。

市場趨勢

穿戴式輸液設備在慢性病治療領域的普及，從根本上改變了給藥環境，使患者能夠在臨床環境之外管理複雜的治療方案。與傳統的腸外給藥方式不同，這些隱藏的無管系統能夠持續皮下輸注大劑量生物製藥，直接滿足了患者對生活方式導向治療方案的需求。這種轉變在糖尿病管理領域尤其明顯，自動給藥系統的需求正在激增。根據Insullet公司於2024年11月發布的2024年第三季財報，其季度銷售額達到5.439億美元，年增25.7%。這主要歸功於該公司OmniPod 5自動胰島素給藥系統的快速普及，顯示整個產業正在向將藥物儲存和給藥功能整合到單一、便於患者使用的單元中的設備轉變。

採用互聯智慧設備監測用藥依從性，標誌著數位醫療和藥物傳輸技術的顯著整合。製造商正擴大將藍牙和感測器技術等連接功能整合到其藥物傳輸系統中，以即時收集給藥數據，為醫療專業人員提供可操作的洞察，並提高患者的用藥依從性。這種整合建構了閉合迴路生態系統，使藥物傳輸設備能夠直接與行動應用程式通訊，實現劑量追蹤和演算法調整的自動化。根據Ipsomed Holding AG於2024年11月發布的《2024/25財政年度半年報》，其mylife Loop解決方案（將胰島素幫浦與基於智慧型手機的演算法連接）截至2024年9月底已擁有約6萬用戶。這顯示市場正從簡單的機械工具發展到能夠最佳化治療效果的智慧數據生成平台。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球藥物輸送市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 給藥途徑（口服給藥、鼻腔給藥、眼部給藥、局部給藥、其他）
    • 依應用領域（癌症、感染疾病、糖尿病、心血管疾病等）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美藥物輸送市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲藥物輸送市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區藥物傳輸市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲藥物輸送市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲藥物輸送市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章 全球藥物輸送市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Johnson & Johnson
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • Bayer AG
  • Antares Pharma, Inc.
  • Becton, Dickinson and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Amgen, Inc.
  • AbbVie Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 23145

The Global Pharmaceutical Drug Delivery Market is projected to expand from a valuation of USD 2.12 Billion in 2025 to USD 2.97 Billion by 2031, reflecting a CAGR of 5.76%. This sector is defined by specialized systems and formulations designed to transport therapeutic agents to targeted physiological sites, thereby ensuring maximum medical efficacy. The market is primarily underpinned by the increasing global incidence of chronic diseases and the burgeoning biologics sector, which demands precise administration techniques beyond conventional oral routes. Illustrating the significant capital driving these advanced technologies, the European Federation of Pharmaceutical Industries and Associations estimated in 2024 that the research-based pharmaceutical industry invested €55,000 million in R&D across Europe.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.12 Billion
Market Size 2031USD 2.97 Billion
CAGR 2026-20315.76%
Fastest Growing SegmentTopical Drug Delivery
Largest MarketNorth America

However, the market faces considerable obstacles due to the rigorous regulatory framework governing new delivery vehicles and combination products. The approval process for advanced systems, such as nanotechnology-based carriers, is intricate, often requiring extensive clinical validation and incurring exorbitant development costs. These regulatory demands create high barriers to entry and can significantly postpone commercialization, potentially hindering the rapid introduction of innovative delivery solutions to the global landscape.

Market Driver

The escalating burden of chronic and non-communicable diseases acts as a major catalyst for the global drug delivery market, necessitating the deployment of targeted and sustained-release mechanisms. In the field of oncology, there is an intensifying demand for antibody-drug conjugates and nanoparticle carriers to enhance therapeutic indices. According to the American Cancer Society's 'Cancer Facts & Figures 2024', released in January 2024, new cancer diagnoses in the United States are projected to exceed 2 million for the first time, underscoring the critical need for precision delivery systems. This epidemiological shift compels manufacturers to focus on developing formulations and devices that ensure medication adherence and efficacy for long-term management.

Simultaneously, the sector is being propelled by increased R&D investments in complex drug formulation and lifecycle management, particularly to support the expanding biologics pipeline. Pharmaceutical companies are allocating substantial capital to resolve stability and bioavailability challenges associated with large-molecule therapeutics through innovative delivery vehicles. As per the '2024 PhRMA Annual Membership Survey' published in September 2024, member companies reported a record-high $103.1 billion investment in research and development during 2023, a financial commitment that accelerates the commercialization of advanced technologies. Furthermore, the U.S. Food and Drug Administration noted in 2024 that the Center for Drug Evaluation and Research approved 55 novel therapeutics in the preceding year, significantly broadening the landscape of products requiring specialized administration.

Market Challenge

The stringent regulatory landscape regarding novel delivery vehicles constitutes a primary restraint on the growth of the global pharmaceutical drug delivery market. Regulatory bodies enforce rigorous standards for combination products and advanced carriers, requiring manufacturers to conduct extensive and prolonged clinical trials to demonstrate safety and efficacy. This complex approval process extends development timelines significantly, delaying the commercial availability of new delivery systems. Consequently, companies face prolonged periods of uncertainty and delayed return on investment, which discourages the pursuit of high-risk innovative projects and limits the volume of new products entering the market.

These regulatory hurdles directly translate into substantial financial burdens, creating a high barrier to entry that hampers market expansion. The necessity for comprehensive validation data forces manufacturers to allocate immense resources to the research phase, often making development financially unviable for smaller entities. According to the Pharmaceutical Research and Manufacturers of America, in 2024, member companies reported a record research and development expenditure of $103.5 billion, reflecting the escalating costs associated with navigating these demanding development pathways. This intense financial pressure restricts the ability of market players to introduce diverse solutions rapidly, thereby slowing the overall trajectory of the sector.

Market Trends

The proliferation of wearable on-body injectors for chronic conditions is fundamentally reshaping the administration landscape by enabling patients to manage complex therapies outside clinical settings. Unlike traditional parenteral methods, these discreet, tubeless systems offer continuous subcutaneous delivery of large-volume biologics, directly addressing the need for lifestyle-compatible treatment options. This shift is particularly evident in the diabetes management sector, where the demand for automated delivery systems is surging. According to Insulet Corporation's 'Third Quarter 2024 Financial Results' from November 2024, the company reported quarterly revenue of $543.9 million, a 25.7% increase year-over-year, driven largely by the rapid adoption of its Omnipod 5 automated insulin delivery system, indicating a broader industry move toward devices that combine medication storage and propulsion into a single, patient-friendly unit.

The adoption of connected smart devices for adherence monitoring represents a pivotal convergence of digital health and medication delivery technologies. Manufacturers are increasingly embedding connectivity features such as Bluetooth and sensor technology into delivery systems to capture real-time dosing data, thereby enhancing patient compliance and providing actionable insights for healthcare providers. This integration allows for the creation of closed-loop ecosystems where administration devices communicate directly with mobile applications to automate dosage tracking and algorithmic adjustments. According to Ypsomed Holding AG's 'Semiannual Report 2024/25' released in November 2024, the company's mylife Loop solution, which connects an insulin pump to a smartphone-based algorithm, reached approximately 60,000 users by the end of September 2024, underscoring the market's evolution from simple mechanical tools to intelligent data-generating platforms that optimize therapeutic outcomes.

Key Market Players

  • Johnson & Johnson
  • Novartis International AG
  • F. Hoffmann-La Roche AG
  • Pfizer Inc.
  • Bayer AG
  • Antares Pharma, Inc.
  • Becton, Dickinson and Company
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Amgen, Inc.
  • AbbVie Inc.

Report Scope

In this report, the Global Pharmaceutical Drug Delivery Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Drug Delivery Market, By Route of Administration

  • Oral drug delivery
  • Nasal drug delivery
  • Ocular drug delivery
  • Topical drug delivery
  • Others

Pharmaceutical Drug Delivery Market, By Application

  • Cancer
  • Infectious Diseases
  • Diabetes
  • Cardiovascular Diseases
  • Others

Pharmaceutical Drug Delivery Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Drug Delivery Market.

Available Customizations:

Global Pharmaceutical Drug Delivery Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Drug Delivery Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Route of Administration (Oral drug delivery, Nasal drug delivery, Ocular drug delivery, Topical drug delivery, Others)
    • 5.2.2. By Application (Cancer, Infectious Diseases, Diabetes, Cardiovascular Diseases, Others)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Pharmaceutical Drug Delivery Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Route of Administration
    • 6.2.2. By Application
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Pharmaceutical Drug Delivery Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Route of Administration
        • 6.3.1.2.2. By Application
    • 6.3.2. Canada Pharmaceutical Drug Delivery Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Route of Administration
        • 6.3.2.2.2. By Application
    • 6.3.3. Mexico Pharmaceutical Drug Delivery Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Route of Administration
        • 6.3.3.2.2. By Application

7. Europe Pharmaceutical Drug Delivery Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Route of Administration
    • 7.2.2. By Application
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Pharmaceutical Drug Delivery Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Route of Administration
        • 7.3.1.2.2. By Application
    • 7.3.2. France Pharmaceutical Drug Delivery Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Route of Administration
        • 7.3.2.2.2. By Application
    • 7.3.3. United Kingdom Pharmaceutical Drug Delivery Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Route of Administration
        • 7.3.3.2.2. By Application
    • 7.3.4. Italy Pharmaceutical Drug Delivery Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Route of Administration
        • 7.3.4.2.2. By Application
    • 7.3.5. Spain Pharmaceutical Drug Delivery Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Route of Administration
        • 7.3.5.2.2. By Application

8. Asia Pacific Pharmaceutical Drug Delivery Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Route of Administration
    • 8.2.2. By Application
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Pharmaceutical Drug Delivery Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Route of Administration
        • 8.3.1.2.2. By Application
    • 8.3.2. India Pharmaceutical Drug Delivery Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Route of Administration
        • 8.3.2.2.2. By Application
    • 8.3.3. Japan Pharmaceutical Drug Delivery Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Route of Administration
        • 8.3.3.2.2. By Application
    • 8.3.4. South Korea Pharmaceutical Drug Delivery Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Route of Administration
        • 8.3.4.2.2. By Application
    • 8.3.5. Australia Pharmaceutical Drug Delivery Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Route of Administration
        • 8.3.5.2.2. By Application

9. Middle East & Africa Pharmaceutical Drug Delivery Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Route of Administration
    • 9.2.2. By Application
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Pharmaceutical Drug Delivery Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Route of Administration
        • 9.3.1.2.2. By Application
    • 9.3.2. UAE Pharmaceutical Drug Delivery Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Route of Administration
        • 9.3.2.2.2. By Application
    • 9.3.3. South Africa Pharmaceutical Drug Delivery Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Route of Administration
        • 9.3.3.2.2. By Application

10. South America Pharmaceutical Drug Delivery Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Route of Administration
    • 10.2.2. By Application
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Pharmaceutical Drug Delivery Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Route of Administration
        • 10.3.1.2.2. By Application
    • 10.3.2. Colombia Pharmaceutical Drug Delivery Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Route of Administration
        • 10.3.2.2.2. By Application
    • 10.3.3. Argentina Pharmaceutical Drug Delivery Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Route of Administration
        • 10.3.3.2.2. By Application

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Pharmaceutical Drug Delivery Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Johnson & Johnson
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Novartis International AG
  • 15.3. F. Hoffmann-La Roche AG
  • 15.4. Pfizer Inc.
  • 15.5. Bayer AG
  • 15.6. Antares Pharma, Inc.
  • 15.7. Becton, Dickinson and Company
  • 15.8. GlaxoSmithKline plc
  • 15.9. Merck & Co., Inc.
  • 15.10. Amgen, Inc.
  • 15.11. AbbVie Inc.

16. Strategic Recommendations

17. About Us & Disclaimer